| ￥1500 | |
| RP-A00055-0.2 | |
|
|
|
|
|
|
|
|
|
MAD7 is a novel nuclease that was released by Inscripta in 2017. This nuclease only requires a crRNA for gene editing and allows for specific targeting of AT rich regions of the genome. MAD7 cleaves DNA with a staggered cut as compared to S. pyogenes which has blunt cutting. |
| Form | Liquid |
| Concentration | 1mg/mL |
| Full mRNA length | 4153 nt |
| Full mRNA Molecular Weight | 1.34×10^6 Da |
| Storage buffer | 1mM Sodium citrate, pH 6.5 |
| Storage condition | Store at -20°C for short term (<3 months), store at -80°C for long term. |
| Appearance | Clear and free of foreign particles |
| RNA Length | Expected size band detected |
| RNA Content | Target ± 5% |
| Integrity | ≥ 75% |
| OD260/OD280 | 1.70 ~ 2.30 |
| Capping Efficiency | ≥ 90% |
| Endotoxin | < 10 EU/mg |
| pH | Target ± 0.5 |
| Transfect 2μg of MAD7 mRNA and 0.4μg of guide RNA into 5×104 HEK293T cells through Lipofectamine™ MessengerMAX™ (or equivalent). 48-72 hours after transfection, extract genomic DNA, and amplify the target region by PCR. Analyze the PCR products through NGS sequencing. |
»
Editing efficiency of MAD7 on DNMT target using different guides. »
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
